Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
This simple practice creates a clear record that can be invaluable
BPC-157 is banned owing to dosing concerns, overall effectiveness, safety profile, and lack of human clinical trials
Whether this translates into measurable longevity benefit in humans is a question that awaits the randomized trials that the field urgently needs
